Century Therapeutics (NASDAQ:IPSC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Century Therapeutics (NASDAQ:IPSC – Free Report) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research note on Tuesday, September 29th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Century Therapeutics currently has a consensus rating of “Hold” and an average price target of $4.75.

Get Our Latest Research Report on IPSC

Century Therapeutics Stock Down 0.6%

NASDAQ IPSC opened at $1.64 on Friday. The company has a market capitalization of $296.95 million, a price-to-earnings ratio of -2.56 and a beta of 1.78. Century Therapeutics has a twelve month low of $0.43 and a twelve month high of $3.04. The stock has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $2.06.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. Research analysts expect that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of IPSC. Commodore Capital LP bought a new position in shares of Century Therapeutics in the 1st quarter worth about $19,652,000. BlackRock Inc. bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $19,825,000. Seven Fleet Capital Management LP bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $10,652,174. Trails Edge Capital Partners LP bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $10,130,674. Finally, Spruce Street Capital LP acquired a new stake in Century Therapeutics during the second quarter worth approximately $9,944,682. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.

Further Reading

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.